B
Bull
Bull · 25%MDXH
$3.36
Szenariopreis
$0.720
+0.000 (+0.01%)Zum Schluss
Loading chart…
- High
- 0.740
- Open
- 0.710
- VWAP
- 0.72
- Vol
- 197.03K
- Mkt Cap
- 64.67M
- Low
- 0.710
- Amount
- 142.54K
- EV/EBITDA, TTM
- -31.67
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
AI analysis of MDxHealth SA (MDXH)
holdMDxHealth is not a strong buy right now due to its current price of $0.72, which is significantly below the analyst price target of $2. The company has a forward P/E of 27.7, indicating high expectations for future earnings, but it also has a concerning YTD change of -78.99%, reflecting substantial losses this year. Additionally, the company faces risks related to compliance with Nasdaq's minimum bid price requirement, which could lead to delisting if it fails to close above $1.00 for 10 consecutive days by December 28, 2026.
Bewertungskennzahlen
The current forward P/E ratio for MDxHealth SA (MDXH) is 27.70, compared to its 5-year average forward P/E of 4.08.
Alphio AI Price Scenarios for MDXH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
9.508-21NASDAQ.COMMDxHealth Reports Strong Q2 Performance with Revenue Growth
9.508-21Yahoo FinanceMDxHealth Reports Strong Q2 2026 Earnings with Significant Revenue Growth
9.508-14NewsfilterNeOnc's Clinical Data Exceeds Expectations, Stock Price May Face Major Adjustment
7.007-27NASDAQ.COMMDxHealth Receives Nasdaq Notification on Minimum Bid Price Deficiency
7.007-24seekingalphaMdxhealth SA Receives Nasdaq Compliance Notification
MDXH FAQ — answered by Alphio AI
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States. It operates in the Healthcare sector.
MDxHealth is not a strong buy right now due to its current price of $0.72, which is significantly below the analyst price target of $2. The company has a forward P/E of 27.7, indicating high expectations for future earnings, but it also has a concerning YTD change of -78.99%, reflecting substantial losses this year. Additionally, the company faces risks related to compliance with Nasdaq's minimum bid price requirement, which could lead to delisting if it fails to close above $1.00 for 10 consecutive days by December 28, 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.